MA-RHINOSTICS
9.6.2021 14:02:09 CEST | Business Wire | Press release
Safeguard DNA Diagnostics Inc, SDDI, one of the largest chains of infectious disease laboratories in the Philippines, has introduced COVID sample collection using the Rhinosticsᵗᵐ dry nasal and nasopharyngeal collection swabs. The dry swabs are being introduced at its facilities in Metro Manila, Davao and Negros Occidental. In addition, SDDI will act as the exclusive distributor of Rhinostics in the Philippines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005070/en/
Rhinostics Inc. is a Harvard University spinout company launched to bring new materials and designs for improved sample collection for COVID and broader non-COVID respiratory testing. The Rhinosticsᵗᵐ swabs received a U.S. Emergency Use Authorization (EUA) for COVID sample collection. These swabs allow more comfortable collection, dry shipment and transport without viral transport media.
Paul Jochico, co-Founder and Director of Safeguard DNA Diagnostics, Inc. commented, “We are excited to bring the Rhinostics’ innovative sample collection swabs to the Philippines, to offer our people a more comfortable collection combined with strong assay performance. The dry swabs are more robust and offer lower risk for contamination during collection and transport than VTM and saliva collection devices. Continued COVID testing will help keep more people safe until vaccinations can become widespread in the Philippines.”
George Aaron, CEO and Chairman of Safeguard Biosystems Holdings Ltd, the joint venture partner in SDDI, remarked, “The opportunity to repurpose our molecular microbiology laboratory in Manila provided significant benefits to the people of the Philippines during this unfortunate pandemic. Safeguard remains committed to bringing innovative products for the diagnosis of infectious disease into SDDI’s operations.”
“We could not ask for a better partner to implement our collection swab technology in the Philippines, bringing the newest technology for dry collection, transport and assay performance to the country. SDDI remains an innovator in the diagnostics space in the Philippines, bringing newest technologies to market,” said Cheri Walker, Chief Executive Officer of Rhinostics.
About Safeguard DNA Diagnostics, Inc
Safeguard DNA Diagnostics Inc. (SDDI) is a Philippine Joint Venture company with an equal partnership between Safeguard Biosystems and the interests of Paul Jochico, established to provide Molecular Microbiology diagnostic laboratory services. It delivers rapid detection and identification to COVID-19 and other infectious diseases for the Philippine population.
About Safeguard Biosystems
Safeguard Biosystems is an international molecular diagnostics group that has developed a low cost, high-throughput, molecular diagnostic technology platform. The system enables rapid identification by DNA of the most prevalent bacterial and fungal pathogens directly from blood. Clinical samples can be tested from matrices such as whole blood, urine, peritoneal fluid, and swabs
Safeguard Biosystems is a UK company, incorporated in 2006 and headquartered in Northvale, New Jersey. Safeguard Biosystems’ technology has also been adapted to provide innovative pathogen solutions for Dairy, delivering practical solutions for advanced dairy industry challenges to ensure safe dairy food and healthy herds.
About Rhinostics Inc.:
Rhinostics commercializes simple and elegant solutions to bring better materials, efficiencies and cost savings to the laboratory workflow. The RHINOstic™ automated nasal swab provides features that increase sample throughput by more than 10-fold while removing labor and errors from the laboratory workflow. The swab is integrated onto a cap that can be automated for removal from the tube and rapid accessioning using the 2D barcode on the bottom of the tubes. The product provides an immediate impact to increasing COVID testing efficiencies while being applicable to broader respiratory viral, bacterial, and genetic testing using the polymerase chain reaction (PCR) and next generation sequencing (NGS). In addition, the company offers both a standard nasal swab and nasopharyngeal swab that allow dry shipment, sample concentration and better assay performance. The Rhinostics suite of collection products are registered as Class I exempt medical devices with the FDA and are available for purchase. To learn more, visit https://www.rhinostics.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005070/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s
Arthur D. Little GEMRIX 2026 Report: The EV TRANSITION is Now an Ecosystem Race, With China Setting the Global Pace24.9.2026 12:15:00 CEST | Press release
Ecosystem, not vehicle technology is now decisive in electric vehicle (EV) adoption, and is responsible for sharp differences between markets. This is the key finding of Arthur D. Little (ADL)'s 2026 Global Electric Mobility Readiness Index (GEMRIX), which shows where ecosystems are ready and where structural gaps hold EVs back. China and Norway have both passed the point where EVs have achieved parity with internal combustion engine (ICE) vehicles. The most comprehensive study of its kind, the third edition of GEMRIX assesses 31 markets across five dimensions: macro factors, EV market/competition, customer readiness, public charging infrastructure, total cost of ownership and regulation. A score of 100 indicates broad market-readiness parity between EVs and ICE vehicles. The study highlights three global conclusions: A small group has pulled ahead. China (106) and Norway (103) are the only markets above 100; Singapore (96) and the Netherlands (90) follow closely. Sustained adoption co
Hytera Launches DIB-R6 SMART to Simplify TETRA Infrastructure and Enable Flexible Capacity Scaling24.9.2026 11:50:00 CEST | Press release
Delivering SDR-powered capacity scaling, single-person deployment, and off-grid readiness, the new digital integrated base station cuts CAPEX and OPEX and deployment friction across public safety, energy and industrial networks. Hytera Communications, a leading global provider of critical communications technologies and solutions, announced the launch of the DIB-R6 SMART, a next-generation TETRA Digital Integrated Base Station. Engineered to simplify deployment and reduce the total cost of ownership (TCO) of mission-critical networks, it combines a multi-carrier Software-Defined Radio (SDR) architecture with operational reliability and multi-layer security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923810257/en/ Hytera DIB-R6 SMART TETRA Digital Integrated Base Station "Critical communications cannot afford the luxury of downtime, nor should operators be constrained by rigid, overweight legacy hardware," said Calvin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom